Cytokine News and Research

RSS

Do Artemisia annua L. compounds have SARS-CoV-2 antiviral potential?

Caused by SARS-CoV-2, the ongoing COVID-19 pandemic has led to over 121.2 million cases and over 2.6 million deaths worldwide. An interesting new study examines the potential antiviral activity of compounds present in the plant Artemisia annua L.

18 Mar 2021

COVID-19 is more difficult to diagnose in children and adolescents, finds study

The ongoing pandemic of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread to over 192 countries and territories, causing an enormous loss of lives and economic devastation.

17 Mar 2021

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

A discovery by University of Queensland pain researchers may allow some future cancer patients, including children with leukemia, to avoid their chemotherapy's worst and most debilitating side effects.

15 Mar 2021

Which biomarkers can help predict severe COVID-19?

The ability to detect potentially fatal illness early on in the course of the disease would enable a swift prioritization of these high-risk individuals for treatment. A new preprint on the medRxiv* server presents an array of biomarkers that may help achieve this laudable goal.

15 Mar 2021

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

Researchers in the United States have conducted a study showing that a cannabis plant compound inhibited infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in human lung cells.

14 Mar 2021

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

A team of researchers led by Thomas W. McDade of Northwestern University suggests people who were previously infected with SARS-CoV-2, the causative agent of COVID-19, may require only one dose of the mRNA vaccine to obtain immunity.

11 Mar 2021

SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study

Researchers found about 10% of blood monocytes in coronavirus disease 2019 (COVID-19) patients are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). These monocytes then die, leading to the release of cytokines – a feature associated with severe and critical COVID-19.

11 Mar 2021

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

A new study deals with the evaluation of adaptive immune response to COVID-19 vaccination in candidates who have recovered from SARS-CoV-2 infection.

11 Mar 2021

SARS-CoV-2 spike S1 subunit induces hypercoagulability

The vascular complications of the condition include a range of various coagulopathies that cause bleeding and thrombocytopenia or a hypercoagulable state. A new preprint research paper posted to the medRxiv server describes the role of a fibrinogen-related protein in inducing these clinical features of COVID-19.

10 Mar 2021

Buck scientists develop a predictive model to help identify people at risk for severe COVID-19

Researchers at the Buck Institute analyzed data from the COVID-19 Symptom Tracker app used by 3 million people in the United Kingdom, adding the use of immunosuppressant medication, use of a mobility aid, shortness of breath, fever, and fatigue to the list of symptoms and comorbidities that increase the risk for severe COVID-19.

9 Mar 2021

CBD ameliorates cognitive function in experimental model of familial Alzheimer's

A two-week course of high doses of CBD helps restore the function of two proteins key to reducing the accumulation of beta-amyloid plaque, a hallmark of Alzheimer's disease, and improves cognition in an experimental model of early onset familial Alzheimer's, investigators report.

9 Mar 2021

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

A new type of CAR T-cell therapy more than triples the expected length of remission for multiple myeloma patients who have relapsed several times, according to an international clinical trial with UT Southwestern as the lead enrolling site.

8 Mar 2021

Rheumatoid arthritis drug improves outcomes in severely ill COVID-19 patients, finds new trial

Tocilizumab, an anti-inflammatory drug used to treat rheumatoid arthritis, improves outcomes in severely ill COVID-19 patients, finds the results of a new trial conducted in hospitals across India -- one of the world's most ethnically diverse countries.

8 Mar 2021

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Researchers in the US recently infected a series of human lung and head/neck cancer cell lines with SARS-CoV-2 that expressed varying levels of ACE2 and the TMPRSS2 protease to reassess their role in viral entrance.

8 Mar 2021

Impairments in immune response contribute to severe COVID-19

New research by a team of scientists at University Hospital RWTH Aachen in Germany and Erasmus Medical Centre in The Netherlands characterized changes in CD8+ T cells in response to SARS-CoV-2.

8 Mar 2021

Combined liver-cytokine humanization enhances human red blood cell production and survival

In a new study by the Yale Department of Immunobiology and Yale Cancer Center, researchers report combined liver and growth factor humanization enhances human red blood cell production and survival in circulation the immunodeficient murine host.

5 Mar 2021

Combining terpenes and cannabidiol may be highly active against human coronaviruses

A group of researchers from a well-known technology company in Israel showed a significant antiviral effect of a combination of terpenes and cannabidiol against a human coronavirus strain 229E. This exciting and first-of-its-kind report is currently available on the bioRxiv preprint server.

4 Mar 2021

Cytokine News and Research

Do Artemisia annua L. compounds have SARS-CoV-2 antiviral potential?

COVID-19 is more difficult to diagnose in children and adolescents, finds study

Discovery may help cancer patients to avoid chemotherapy's debilitating side effects

Which biomarkers can help predict severe COVID-19?

Cannabis compound inhibits SARS-CoV-2 replication in human lung cells

People previously infected with SARS-CoV-2 may achieve immunity after one mRNA vaccine dose, finds study

SARS-CoV-2 can infect blood monocytes and trigger inflammation, finds study

Is a single mRNA COVID-19 vaccine dose enough for recovered individuals?

SARS-CoV-2 spike S1 subunit induces hypercoagulability

Buck scientists develop a predictive model to help identify people at risk for severe COVID-19

CBD ameliorates cognitive function in experimental model of familial Alzheimer's

CAR T-cell therapy triples expected length of remission for relapsed multiple myeloma patients

Rheumatoid arthritis drug improves outcomes in severely ill COVID-19 patients, finds new trial

Study rethinks the role of ACE2 in SARS-CoV-2 viral entry

Impairments in immune response contribute to severe COVID-19

Combined liver-cytokine humanization enhances human red blood cell production and survival

Combining terpenes and cannabidiol may be highly active against human coronaviruses

Novel host-viral-microbiome interactions during COVID-19 may determine outcome

Coronavirus deranges the immune system in complex and deadly ways

Researchers examine long-term immune responses following COVID-19 across clinically diverse cohort

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News